News

The guidelines formalize a stepwise treatment approach ranging from emollients and topical steroids to systemic therapies.

Phase 2/3 brepocitinib trial will target moderate to severe LPP, aiming to calm inflammation and symptoms and potentially deliver the first FDA-approved systemic option.

GLP-1 agonists may aid psoriasis, wound healing, and cardiometabolic health—Daniel Walker, MD, FAAD, explains why dermatologists should start to pay attention.

New studies suggest tattoo pigments migrate to lymph nodes, complicate skin exams, and may raise lymphoma risk—what dermatologists now watch for.

The newly published tool, ODD-SPOT, offers a plain-language, photo-supported alternative to the ABCDE criteria, designed to capture the key warning signs of BCC, SCC, and melanoma in accessible terms.

David Oberlin, MD, shares tips for integrating AAD insights and lessons into the clinic to improve patient care.

Kristen Lo Sicco, MD, shares why scarring alopecia can’t wait as LPP demands early treatment to prevent permanent hair loss amid limited FDA-approved options.

Among systemic-experienced patients, delgocitinib cream still achieved statistically significant efficacy advantages over cream vehicle across all measured outcomes.

GLP-1 therapy may calm psoriasis and hidradenitis suppurativa beyond weight loss, and holistic metabolic care can address aesthetic concerns, according to Walker.

Applications are now open for Allergan Aesthetics' women's entrepreneurship initiative, which provides coaching, community, and grants of up to $20,000 to qualifying business owners.

Dermatologists are exploring GLP-1 drugs for psoriasis and HS, but evidence is early—weight-loss benefits may help as add-ons, not replacements.

The combination of rapid onset and durable response positions zumilokibart as a potentially attractive first-line biologic option.

A cross-sectional study of 403 acne patients found that higher impulsivity scores were significantly associated with both the presence and severity of acne scars.

This review of the latest dermatological studies includes insights on acne in women with hyperandrogenism, fractional CO2 laser and gold microneedling for scarring, oxygen plasma acne treatment, and more.

At AAD 2026, Lauren Madigan, MD, presented long-term PIONEER trial extension data and urged clinicians to sharpen their recognition of 2 clonally driven inflammatory diseases: indolent systemic mastocytosis and VEXAS syndrome.

A new study details the effectiveness of non-invasive HFUS and CDFI technologies for revealing residual disease not captured by clinical evaluation in patients with acne.

Emerging acne therapies like narrow-spectrum antibiotics, hormonal agents, and immunomodulators are promising, more personalized alternatives to isotretinoin, according to new research.

Christopher Bunick, MD, PhD, and Kristian Reich, MD, PhD, discuss phase 3 data presented at AAD showing patients moving from very severe disease at baseline to absent or mild disease by week 40.

Around 80% of clinical trials face enrollment delays, and for rare genodermatoses with small patient pools, AI-generated synthetic control arms may offer a practical path to adequately powered studies.

Patients who are needle-averse may soon have effective non-injectable options with biologic-like results.

At AAD 2026, Diego Ruiz Dasilva, MD, makes the case that the black box warning on JAK inhibitors shouldn't deter appropriate prescribing.

A new review examined the bone–vascular axis in psoriasis and how the current therapeutic toolbox can influence cardiovascular and skeletal health.

The inaugural DermVIP Summit will be held from May 8 to 9 at the New York Academy of Medicine.

Steven Daveluy, MD, discusses how this approval helps close a critical gap in care for adolescents living with HS.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news on phase 3 AD SHORE trials for amlitelimab, the expansion of coverage for tirbanibulin, the start of a phase 2b/3 of brepocitinib for LPP, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.